SCHEMBL64248

SCHEMBL64248

O=C(NC(=S)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
ALOX12 P18054 2/20 0.47
RECQL P46063 1/20 0.47
KCNH2 Q12809 1/20 0.42
CYP2C9 P11712 1/20 0.42
MITF O75030 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ERCC1 P07992 1/20 0.37
FEN1 P39748 1/20 0.37
ERCC4 Q92889 1/20 0.37
ATM Q13315 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.36
EPHX1 P07099 1/20 0.36
CALCA P06881 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52562 0.92 KCNH2 (0.45) ALDH1A1MEN1KMT2ALMNAALOX12
SCHEMBL64246 0.88 KCNH2 (0.46) MEN1KMT2ALMNAKCNH2CYP2C9
SCHEMBL418372 0.87 KCNH2 (0.47) MEN1KMT2AKCNH2CYP2C9SMN1; SMN2
SCHEMBL63876 0.86 KCNH2 (0.46) ALDH1A1MEN1KMT2AKCNH2CYP2C9
SCHEMBL64204 0.86 KCNH2 (0.48) ALDH1A1MEN1KMT2AKCNH2CYP2C9
SCHEMBL52520 0.85 L3MBTL1 (0.47) MEN1KMT2AKCNH2CYP2C9SMN1; SMN2
SCHEMBL52470 0.85 KCNH2 (0.49) MEN1KMT2ALMNAKCNH2CYP2C9
SCHEMBL52473 0.85 KCNH2 (0.43) ALDH1A1KCNH2CYP2C9SMN1; SMN2ERCC1
SCHEMBL62281 0.84 KCNH2 (0.42) ALDH1A1MEN1KMT2ALMNAKCNH2
SCHEMBL64481 0.83 KCNH2 (0.45) MEN1KMT2AKCNH2CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ALDH1A1 539/4885MEN1 4650/4885KMT2A 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.